Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IONS
stocks logo

IONS

-
Add to WatchlistAdvanced Chart
$
0.000
0(0.000%)1D
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
282.95M
+25.75%
0.104
-143.5%
160.54M
+19.8%
-0.863
+19.05%
177.96M
-21.6%
-0.861
+100.15%
Estimates Revision
The market is revising Upward the revenue expectations for Ionis Pharmaceuticals, Inc. (IONS) for FY2025, with the revenue forecasts being adjusted by 13.3% over the past three months. During the same period, the stock price has changed by 47.91%.
Revenue Estimates for FY2025
Revise Upward
up Image
+13.3%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-17.6%
In Past 3 Month
Stock Price
Go Up
up Image
+47.91%
In Past 3 Month
18 Analyst Rating
up Image0
Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 58.33 USD with a low forecast of 38.00 USD and a high forecast of 78.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Buy
5 Hold
0 Sell
Moderate Buy
up Image0
Current: 42.170
sliders
Low
38.00
Averages
58.33
High
78.00
up Image0
Current: 42.170
sliders
Low
38.00
Averages
58.33
High
78.00
Barclays
Equal Weight
to
Overweight
upgrade
$51 -> $57
2025-06-30
Reason
Barclays
Price Target
$51 -> $57
2025-06-30
upgrade
Equal Weight
to
Overweight
Reason
Barclays upgraded Ionis Pharmaceuticals to Overweight from Equal Weight with a price target of $57, up from $51, ahead of Tryngolza Phase 3 CORE/CORE2 data in severe hypertriglyceridemia due likely in September. After having spoken with three key opinion leaders and doing a deep dive on historical clinical trials, natural history data, and statistical analysis, the firm sees a greater than 90% probability that the trial will hit the primary endpoint and sees a high probability it will hit all key second biomarker endpoints, the analyst tells investors.
JPMorgan
Neutral
maintain
$45 -> $48
2025-06-12
Reason
JPMorgan
Price Target
$45 -> $48
2025-06-12
maintain
Neutral
Reason
JPMorgan raised the firm's price target on Ionis Pharmaceuticals to $48 from $45 and keeps a Neutral rating on the shares. The firm updated the company's model to reflect higher Amvuttra estimates.
Needham
Joseph Stringer
Strong Buy
Reiterates
$60
2025-04-15
Reason
Needham
Joseph Stringer
Price Target
$60
2025-04-15
Reiterates
Strong Buy
Reason
Needham
Joseph Stringer
Strong Buy
Reiterates
$60
2025-04-08
Reason
Needham
Joseph Stringer
Price Target
$60
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Mitchell Kapoor
Strong Buy
Initiates
$45
2025-04-07
Reason
HC Wainwright & Co.
Mitchell Kapoor
Price Target
$45
2025-04-07
Initiates
Strong Buy
Reason
Guggenheim
Debjit Chattopadhyay
Strong Buy
Reiterates
n/a
2025-04-03
Reason
Guggenheim
Debjit Chattopadhyay
Price Target
n/a
2025-04-03
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Ionis Pharmaceuticals Inc (IONS.O) is -20.88, compared to its 5-year average forward P/E of -31.73. For a more detailed relative valuation and DCF analysis to assess Ionis Pharmaceuticals Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-31.73
Current PE
-20.88
Overvalued PE
-0.22
Undervalued PE
-63.25

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-21.48
Current EV/EBITDA
-13.40
Overvalued EV/EBITDA
-1.29
Undervalued EV/EBITDA
-41.66

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
9.15
Current PS
8.27
Overvalued PS
10.78
Undervalued PS
7.53

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 242.57% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

IONS News & Events

Events Timeline

(ET)
2025-06-25
07:39:33
Ionis Pharmaceuticals partner Biogen announces results from salanersen study
select
2025-06-12 (ET)
2025-06-12
09:26:58
Ionis announces Geary to retire as Chief Development Officer
select
2025-06-11 (ET)
2025-06-11
07:05:51
Ionis Pharmaceuticals doses first patient in REVEAL study
select
Sign Up For More Events
Sign Up For More Events

News

Preview
9.5
07-16Newsfilter
PinnedIonis to hold second quarter 2025 financial results webcast

  • Webcast Announcement: Ionis Pharmaceuticals will host a live webcast on July 30 at 11:30 a.m. Eastern Time to discuss its Q2 2025 financial results and key program updates, accessible via their investor relations website.

  • Company Overview: Ionis Pharmaceuticals has been innovating RNA-targeted medicines for over 30 years, with six marketed products and a strong pipeline focused on neurology and cardiology, emphasizing their commitment to advancing patient care through innovative therapies.

Preview
8.0
07-15NASDAQ.COM
Noteworthy Monday Option Activity: TPL, LULU, IONS

  • Lululemon Options Trading: Lululemon athletica inc (LULU) experienced significant options trading activity with 33,214 contracts, particularly for the $240 strike call option expiring July 18, 2025, which saw 1,492 contracts traded.

  • Ionis Pharmaceuticals Options Activity: Ionis Pharmaceuticals Inc (IONS) also had notable options trading, with 14,809 contracts traded, focusing on the $45 strike call option expiring September 19, 2025, where 7,025 contracts were exchanged.

Preview
9.0
06-27Newsfilter
New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA

  • New Findings on Nusinersen: Recent analyses from the DEVOTE Part C trial show that a higher dose regimen of nusinersen significantly improves motor function in individuals with spinal muscular atrophy (SMA) who had previously been treated with the standard 12 mg dose. The study demonstrated improvements across various age groups and functional statuses, indicating potential benefits even for those with established disease.

  • Impact of Early Treatment: Final results from the NURTURE study reveal that early treatment with 12 mg SPINRAZA leads to remarkable outcomes in clinically presymptomatic infants with SMA, with 92% achieving independent walking and no participants requiring permanent ventilation throughout the study duration. The treatment was well tolerated, reinforcing its safety profile over eight years.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Ionis Pharmaceuticals Inc (IONS) stock price today?

The current price of IONS is 42.17 USD — it has increased 0 % in the last trading day.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS)'s business?

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

arrow icon

What is the price predicton of IONS Stock?

Wall Street analysts forecast IONS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IONS is 58.33 USD with a low forecast of 38.00 USD and a high forecast of 78.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS)'s revenue for the last quarter?

Ionis Pharmaceuticals Inc revenue for the last quarter amounts to 131.61M USD, increased 10.14 % YoY.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS)'s earnings per share (EPS) for the last quarter?

Ionis Pharmaceuticals Inc. EPS for the last quarter amounts to -0.93 USD, decreased -5.10 % YoY.

arrow icon

What changes have occurred in the market's expectations for Ionis Pharmaceuticals Inc (IONS)'s fundamentals?

The market is revising Upward the revenue expectations for Ionis Pharmaceuticals, Inc. (IONS) for FY2025, with the revenue forecasts being adjusted by 13.3% over the past three months. During the same period, the stock price has changed by 47.91%.
arrow icon

How many employees does Ionis Pharmaceuticals Inc (IONS). have?

Ionis Pharmaceuticals Inc (IONS) has 1069 emplpoyees as of July 18 2025.

arrow icon

What is Ionis Pharmaceuticals Inc (IONS) market cap?

Today IONS has the market capitalization of 6.71B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free